<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04837716</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0838</org_study_id>
    <secondary_id>NCI-2021-02560</secondary_id>
    <secondary_id>2020-0838</secondary_id>
    <nct_id>NCT04837716</nct_id>
  </id_info>
  <brief_title>Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer</brief_title>
  <official_title>A Phase 1b Study of Ensartinib in Combination With Platinum-Based Chemotherapy and Bevacizumab in ALK-Positive Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase Ib trial finds the best dose and side effects of ensartinib and its effects when&#xD;
      given with carboplatin, pemetrexed and bevacizumab for in treating patients with ALK-positive&#xD;
      non-small cell lung cancer that is stage IIIC or IV, or has come back (recurrent). Ensartinib&#xD;
      may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.&#xD;
      Chemotherapy drugs, such as carboplatin and pemetrexed, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells, by stopping them from dividing, or by&#xD;
      stopping them from spreading. Bevacizumab is a monoclonal antibody that may interfere with&#xD;
      the ability of tumor cells to grow and spread. Giving ensartinib, carboplatin, pemetrexed and&#xD;
      bevacizumab may help to control the disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the safety of ensartinib in combination with carboplatin, pemetrexed and&#xD;
      bevacizumab in patients with ALK-rearranged advanced non-small cell lung cancer (NSCLC).&#xD;
&#xD;
      II. Determine the recommended phase 2 dose (RP2D) of ensartinib in combination with&#xD;
      carboplatin, pemetrexed and bevacizumab.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine an objective response rate (ORR) in patients with ALK-rearranged advanced&#xD;
      NSCLC treated with ensartinib in combination with carboplatin, pemetrexed and bevacizumab&#xD;
      using modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1).&#xD;
&#xD;
      II. To determine progression-free survival (PFS). III. To determine overall survival.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. To determine biomarkers associated with response and resistance to the study combination.&#xD;
&#xD;
      OUTLINE: This is a dose de-escalation study of ensartinib and fixed-dose carboplatin,&#xD;
      pemetrexed, and bevacizumab followed by a dose-expansion study.&#xD;
&#xD;
      INDUCTION THERAPY: Patients receive ensartinib orally (PO) once daily (QD) on days 1-21,&#xD;
      carboplatin intravenously (IV) over 15-60 minutes on day 1, pemetrexed IV over 10 minutes on&#xD;
      day 1 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up&#xD;
      to 4 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      MAINTENANCE THERAPY: Patients receive ensartinib PO QD on days 1-21 and bevacizumab IV over&#xD;
      30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2021</start_date>
  <completion_date type="Anticipated">September 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 23, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>The toxicity rate will be estimated with their exact 95% confidence intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended phase 2 dose</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>Will employ the Bayesian optimal interval (BOIN) design (Liu and Yuan, 2015; Yuan et al., 2016) to find the maximum tolerated dose of ensartinib in combination with carboplatin, pemetrexed and bevacizumab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 1.5 years</time_frame>
    <description>Assessed using modified Response Evaluation Criteria in Solid Tumors (1.1). The response rate will be estimated with their exact 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 1.5 years</time_frame>
    <description>Will be estimated using the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 1.5 years</time_frame>
    <description>Will be estimated using the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarkers associated with response and resistance</measure>
    <time_frame>Up to 1.5 years</time_frame>
    <description>The difference in the biomarkers between responders and non-responders will be evaluated by Fisher's exact test for categorical biomarkers or Wilcoxon rank sum test for continuous biomarkers.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Metastatic Lung Non-Small Cell Carcinoma</condition>
  <condition>Recurrent Lung Non-Small Cell Carcinoma</condition>
  <condition>Stage IIIC Lung Cancer AJCC v8</condition>
  <condition>Stage IV Lung Cancer AJCC v8</condition>
  <condition>Stage IVA Lung Cancer AJCC v8</condition>
  <condition>Stage IVB Lung Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Treatment (ensartinib, carboplatin, pemetrexed, bevacizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INDUCTION THERAPY: Patients receive ensartinib PO QD on days 1-21, carboplatin IV over 15-60 minutes on day 1, pemetrexed IV over 10 minutes on day 1 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
MAINTENANCE THERAPY: Patients receive ensartinib PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ensartinib, carboplatin, pemetrexed, bevacizumab)</arm_group_label>
    <other_name>Anti-VEGF</other_name>
    <other_name>Anti-VEGF Humanized Monoclonal Antibody</other_name>
    <other_name>Anti-VEGF rhuMAb</other_name>
    <other_name>Avastin</other_name>
    <other_name>Bevacizumab awwb</other_name>
    <other_name>Bevacizumab Biosimilar BEVZ92</other_name>
    <other_name>Bevacizumab Biosimilar BI 695502</other_name>
    <other_name>Bevacizumab Biosimilar CBT 124</other_name>
    <other_name>Bevacizumab Biosimilar CT-P16</other_name>
    <other_name>Bevacizumab Biosimilar FKB238</other_name>
    <other_name>Bevacizumab Biosimilar GB-222</other_name>
    <other_name>Bevacizumab Biosimilar HD204</other_name>
    <other_name>Bevacizumab Biosimilar HLX04</other_name>
    <other_name>Bevacizumab Biosimilar IBI305</other_name>
    <other_name>Bevacizumab Biosimilar LY01008</other_name>
    <other_name>Bevacizumab Biosimilar MIL60</other_name>
    <other_name>Bevacizumab Biosimilar Mvasi</other_name>
    <other_name>Bevacizumab Biosimilar QL 1101</other_name>
    <other_name>Bevacizumab Biosimilar RPH-001</other_name>
    <other_name>Bevacizumab Biosimilar SCT501</other_name>
    <other_name>Bevacizumab Biosimilar Zirabev</other_name>
    <other_name>Bevacizumab-awwb</other_name>
    <other_name>Bevacizumab-bvzr</other_name>
    <other_name>BP102</other_name>
    <other_name>BP102 Biosimilar</other_name>
    <other_name>HD204</other_name>
    <other_name>Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer</other_name>
    <other_name>Mvasi</other_name>
    <other_name>Recombinant Humanized Anti-VEGF Monoclonal Antibody</other_name>
    <other_name>rhuMab-VEGF</other_name>
    <other_name>SCT501</other_name>
    <other_name>Zirabev</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ensartinib, carboplatin, pemetrexed, bevacizumab)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carboplatinum</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ensartinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (ensartinib, carboplatin, pemetrexed, bevacizumab)</arm_group_label>
    <other_name>X-396</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ensartinib, carboplatin, pemetrexed, bevacizumab)</arm_group_label>
    <other_name>MTA</other_name>
    <other_name>Multitargeted Antifolate</other_name>
    <other_name>Pemfexy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of stage IV (metastatic) or&#xD;
             recurrent or stage IIIc NSCLC (recurrent or stage IIIC NSCLC must be not a candidate&#xD;
             for definitive multimodality therapy)&#xD;
&#xD;
          -  Documented ALK re-arrangement as detected by: (1) fluorescence in situ hybridization&#xD;
             (FISH), (2) immunohistochemistry (IHC), (3) tissue next generation sequencing (NGS),&#xD;
             or (4) cell free deoxyribonucleic acid (cfDNA) NGS using Clinical Laboratory&#xD;
             Improvement Amendments (CLIA) certified laboratory&#xD;
&#xD;
          -  Subjects can be enrolled as (1) treatment naive (2) after progression on any number of&#xD;
             prior ALK tyrosine kinase inhibitors (TKIs). Prior adjuvant platinum-based&#xD;
             chemotherapy and platinum-based chemotherapy for metastatic disease is allowed if&#xD;
             completed &gt; 12 months from the study treatment start date with one exception: a&#xD;
             patient may be eligible if started on chemotherapy while waiting for ALK testing&#xD;
             results, provided no more than two cycles of chemotherapy were administered and no&#xD;
             evidence of disease progression&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1&#xD;
&#xD;
          -  Aged at least 18 years&#xD;
&#xD;
          -  Brain metastases allowed if asymptomatic at study baseline. Patients must be not on&#xD;
             steroids, with the maximum size of brain lesion not exceeding 30 millimeters. If&#xD;
             patients have neurological symptoms or signs due to central nervous system (CNS)&#xD;
             metastases, patients need to complete whole brain radiation or focal treatment at&#xD;
             least 14 days before start of study treatment and be asymptomatic on stable or&#xD;
             decreasing doses of corticosteroids at baseline&#xD;
&#xD;
          -  Ability to swallow and retain oral medications&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1500/mm^3 /L&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin (Hb) at least 9 g/dL (or 5.69 mmol/L) at baseline&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 x upper limit of normal (ULN) or creatinine clearance (CrCl)&#xD;
             &gt;= 60 mL/minute for subjects with creatinine levels &gt; 1.5 x the institutional ULN&#xD;
&#xD;
          -  Serum total bilirubin less than or equal to =&lt; 1.5 x ULN or direct bilirubin =&lt; ULN&#xD;
             for subjects with total bilirubin levels &gt; 1.5 x ULN&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =&lt; 2.5 x ULN&#xD;
             except for subjects with liver metastases (mets) for whom ALT and AST should be =&lt; 5 x&#xD;
             ULN&#xD;
&#xD;
          -  International normalized ratio (INR) or prothrombin time (PT) =&lt; 1.5 x ULN unless&#xD;
             subject is receiving anticoagulant therapy as long as PT or partial thromboplastin&#xD;
             time (PTT) is within therapeutic range of intended use of anticoagulants&#xD;
&#xD;
          -  Activated PTT (aPTT) =&lt; 1.5 x ULN unless subject is receiving anticoagulant therapy if&#xD;
             PT or PTT is within therapeutic range of intended use of anticoagulant&#xD;
&#xD;
          -  Female patients of childbearing potential must have a negative pregnancy test&#xD;
             documented at time of screening&#xD;
&#xD;
          -  Female patients who:&#xD;
&#xD;
               -  Are postmenopausal for at least 1 year before the screening visit, OR&#xD;
&#xD;
               -  Are surgically sterile, OR&#xD;
&#xD;
               -  If they are of childbearing potential, agree to use a highly effective method of&#xD;
                  contraception from the time of signing the informed consent through 4 months&#xD;
                  after the last dose of study drug, or agree to completely abstain from&#xD;
                  heterosexual intercourse&#xD;
&#xD;
          -  Male patients, even if surgically sterilized (i.e., status post-vasectomy), who:&#xD;
&#xD;
               -  Agree to practice effective barrier contraception during the entire study&#xD;
                  treatment period and through 4 months after the last dose of study drug, or&#xD;
&#xD;
               -  Agree to completely abstain from heterosexual intercourse&#xD;
&#xD;
          -  Voluntary agreement to provide written informed consent and the willingness and&#xD;
             ability to comply with all aspects of the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of an investigational drug within 21 days prior to the first dose of study drug.&#xD;
             Note that to be eligible, any drug-related toxicity should have recovered to grade 2&#xD;
             or less, with the exception of alopecia&#xD;
&#xD;
          -  Major surgery within the last 4 weeks or radiotherapy within the last 14 days&#xD;
&#xD;
          -  Patients with leptomeningeal disease are ineligible&#xD;
&#xD;
          -  Patients with a previous malignancy within the past 2 years (other than curatively&#xD;
             treated basal cell carcinoma of the skin, in situ carcinoma of the cervix, or any&#xD;
             cancer that is considered to be cured and have no impact on PFS and overall survival&#xD;
             [OS] for the current NSCLC)&#xD;
&#xD;
          -  Concomitant systemic use of anticancer herbal medications. These should be stopped&#xD;
             prior to study entry&#xD;
&#xD;
          -  Patients receiving:&#xD;
&#xD;
               -  Strong CYP3A inhibitors (including, but not limited to, atazanavir,&#xD;
                  clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir,&#xD;
                  ritonavir, saquinavir, telithromycin, voriconazole, grapefruit, grapefruit juice)&#xD;
&#xD;
               -  Strong CYP3A inducers (including, but not limited to, carbamazepine,&#xD;
                  phenobarbital, phenytoin, rifabutin, rifampin, St. John's wort)&#xD;
&#xD;
               -  CYP3A substrates with narrow therapeutic window (including, but not limited to,&#xD;
                  alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide,&#xD;
                  quinidine, sirolimus, tacrolimus)&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Presence of active gastrointestinal (GI) disease or other condition that will&#xD;
             interfere significantly with the absorption, distribution, metabolism, or excretion of&#xD;
             study medications&#xD;
&#xD;
          -  Patients at risk for GI perforation&#xD;
&#xD;
          -  Clinically significant cardiovascular disease including:&#xD;
&#xD;
               -  Corrected QT per Fridericia's formula (QTcF) interval &gt; 450 ms for men and &gt; 470&#xD;
                  ms for women, symptomatic bradycardia &lt; 45 beats per minute or other significant&#xD;
                  electrocardiogram (ECG) abnormalities in the investigator's opinion&#xD;
&#xD;
               -  Clinically uncontrolled hypertension in the investigator's opinion (e.g., blood&#xD;
                  pressure &gt; 160/100 mmHg; note that isolated elevated readings considered to not&#xD;
                  be indicative of uncontrolled hypertension are allowed)&#xD;
&#xD;
               -  The following within 6 months prior to cycle 1 day 1:&#xD;
&#xD;
                    -  Congestive heart failure (New York Heart class III or IV)&#xD;
&#xD;
                    -  Arrhythmia or conduction abnormality requiring medication. Note: patients&#xD;
                       with atrial fibrillation/flutter controlled by medication and arrhythmias&#xD;
                       controlled by pacemakers are eligible&#xD;
&#xD;
                    -  Severe/unstable angina, coronary artery/peripheral bypass graft, or&#xD;
                       myocardial infarction&#xD;
&#xD;
                    -  Cerebrovascular accident or transient ischemia&#xD;
&#xD;
          -  Patients who are immunosuppressed (including known human immunodeficiency virus [HIV]&#xD;
             infection), have a serious active infection at the time of treatment, have&#xD;
             interstitial lung disease/pneumonitis, or have any serious underlying medical&#xD;
             condition that would impair the ability of the patient to receive protocol treatment.&#xD;
             Patients with controlled hepatitis C, in the investigator's opinion, are allowed.&#xD;
             Patients with known hepatitis B must be hepatitis B virus e antigen (HBeAg) and HB&#xD;
             viral deoxyribonucleic acid (DNA) negative for enrollment. Note that, because of the&#xD;
             high prevalence, all patients in the Asia-Pacific region (except Australia, New&#xD;
             Zealand, and Japan) must be tested and, if hepatitis B surface antigen (HBsAg)&#xD;
             positive, must be HBeAg and HB viral DNA negative for enrollment&#xD;
&#xD;
          -  Known hypersensitivity to tartrazine, a dye used in the ensartinib 100 mg capsule&#xD;
&#xD;
          -  Concurrent condition that in the investigator's opinion would jeopardize compliance&#xD;
             with the protocol or would impart excessive risk associated with study participation&#xD;
             that would make it inappropriate for the patient to be enrolled&#xD;
&#xD;
          -  Inability or unwillingness to comply with study and/or follow-up procedures outlined&#xD;
             in the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yasir Y Elamin</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasir Y. Elamin</last_name>
      <phone>713-792-6363</phone>
      <email>yyelamin@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Yasir Y. Elamin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 5, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Ensartinib</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

